Is MGM-15 Legal in Arkansas? (2026)

Instrument

Arkansas Schedule I opium-derivatives chapeau (unqualified isomers) + hallucinogen paragraph optical/positional/geometric limiter (scoped away)

Source

https://healthy.arkansas.gov/wp-content/uploads/Controlled-Substances-List-7.3.25.pdf

Retrieved

2026-07-06

Fingerprint

62ad8446e3007192

Arkansas Dept. of Health, List of Controlled Substances (rule; auth. Ark. Code Ann. 5-64-216 & 5-64-101 et seq.), Schedule I:
(c) Opium derivatives (Narcotic Drugs) - governing chapeau for the mitragynine listing:
"(c) Opium derivatives: (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:"
Entries:
"(24) Mitragynine (11-2015)"
“(25) 7-Hydroxymitragynine (11-2015)”

(d) Hallucinogenic substances chapeau - the optical/positional/geometric limiter, expressly scoped to (d) ONLY (does NOT govern the (c) mitragynine listing):
"...(for purposes of this paragraph only, the term \"isomer\“ includes the optical, position and geometric isomers):”

Ark. Code Ann. 5-64-101 (Definitions): no general definition of "isomer."

Instrument

Controlled substance analog

Source

https://law.onecle.com/arkansas/title-5/5-64-414.html

Retrieved

2026-10-28

Fingerprint

47e5ce6e9fe57a81

(a)

(1)
 “Controlled substance analog” means a substance:

(A)
 The chemical structure of which is substantially similar to the chemical structure of a controlled substance in Schedule I or Schedule II or that has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or Schedule II; or

(B)
 With respect to a particular individual, that the individual represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or Schedule II.

(2)
 “Controlled substance analog” does not include:

(A)
 A controlled substance;

(B)
 A substance for which there is an approved new drug application;

(C)
 A substance with respect to which an exemption is in effect for investigational use by a particular person under § 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is pursuant to the exemption; or

(D)
 Any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance.
(b)
 A controlled substance analog, to the extent intended for human consumption, is treated for the purposes of this chapter as a substance included in Schedule I.
(c)
 Within ten (10) days after the initiation of prosecution with respect to a controlled substance analog by indictment or information, the prosecuting attorney shall notify the Director of the Department of Health of information relevant to emergency scheduling as provided for in § 5-64-201(d).
(d)
 After final determination that the controlled substance analog should not be scheduled, no prosecution relating to that substance as a controlled substance analog may continue or take place.

Instrument

Controlled substance analog

Source

https://www.arkleg.state.ar.us/Home/FTPDocument?path=%2FACTS%2F2005%2FPublic%2FACT1994.pdf

Retrieved

2026-10-29

Fingerprint

cfa185d5722e7286

(a)(1)  “Controlled substance analog” means a substance the chemical

26

structure of which is substantially similar to the chemical structure of a

27

controlled substance in Schedule I or II or which has a stimulant,

28

depressant, or hallucinogenic effect on the central nervous system

29

substantially similar to the stimulant, depressant, or hallucinogenic effect

30

on the central nervous system of a controlled substance included in Schedule

31

I or II; or with respect to a particular individual, which the individual

32

represents or intends to have a stimulant, depressant, or hallucinogenic

33

effect on the central nervous system substantially similar to the stimulant,

34

depressant, or hallucinogenic effect on the central nervous system of a

35

controlled substance included in Schedule I or II.

36

            (2)  The term does not include:

238

03-31-2005 14:29  GRH242

As Engrossed: H3/31/05

SB984

1

2

3

4

5

6

7

8

9

                  (A)  A controlled substance;

                  (B)  A substance for which there is an approved new drug

application;

                  (C)  A substance with respect to which an exemption is in

effect for investigational use by a particular person under section 505 of

the Federal Food, Drug and Cosmetic Act to the extent conduct with respect to

the substance is pursuant to the exemption; or

                  (D)  Any substance to the extent not intended for human

consumption before an exemption takes effect with respect to the substance.

10

(b)  A controlled substance analog, to the extent intended for human

11

consumption, shall be treated, for the purposes of subchapters 1-6 of this

12

chapter, as a substance included in Schedule I.

13

(c)  Within ten (10) days after the initiation of prosecution with

14

respect to a controlled substance analog by indictment or information, the

15

prosecuting attorney shall notify the Director of the Department of Health of

16

information relevant to emergency scheduling as provided for in § 5-64-

17

201(d).

18

(d)  After final determination that the controlled substance analog

19

should not be scheduled, no prosecution relating to that substance as a

20

controlled substance analog may continue or take place.